IL31384A - Pharmaceutical preparations containing a vasotoxic effect of the hepatic acid of type peptide and 9-) 1-methyl-4-piperidilide (thioxanthane - Google Patents

Pharmaceutical preparations containing a vasotoxic effect of the hepatic acid of type peptide and 9-) 1-methyl-4-piperidilide (thioxanthane

Info

Publication number
IL31384A
IL31384A IL31384A IL3138469A IL31384A IL 31384 A IL31384 A IL 31384A IL 31384 A IL31384 A IL 31384A IL 3138469 A IL3138469 A IL 3138469A IL 31384 A IL31384 A IL 31384A
Authority
IL
Israel
Prior art keywords
caffeine
mepithiathene
methyl
vasotonic
thioxanthene
Prior art date
Application number
IL31384A
Other languages
English (en)
Hebrew (he)
Other versions
IL31384A0 (en
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL31384A0 publication Critical patent/IL31384A0/xx
Publication of IL31384A publication Critical patent/IL31384A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL31384A 1968-01-09 1969-01-08 Pharmaceutical preparations containing a vasotoxic effect of the hepatic acid of type peptide and 9-) 1-methyl-4-piperidilide (thioxanthane IL31384A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH35068 1968-01-09

Publications (2)

Publication Number Publication Date
IL31384A0 IL31384A0 (en) 1969-03-27
IL31384A true IL31384A (en) 1972-10-29

Family

ID=4185009

Family Applications (1)

Application Number Title Priority Date Filing Date
IL31384A IL31384A (en) 1968-01-09 1969-01-08 Pharmaceutical preparations containing a vasotoxic effect of the hepatic acid of type peptide and 9-) 1-methyl-4-piperidilide (thioxanthane

Country Status (11)

Country Link
US (1) US3557287A (fr)
AT (1) AT305491B (fr)
BE (1) BE726570A (fr)
BR (1) BR6905370D0 (fr)
CA (1) CA921402A (fr)
DE (1) DE1900307A1 (fr)
FR (1) FR8187M (fr)
GB (1) GB1247801A (fr)
IE (1) IE32612B1 (fr)
IL (1) IL31384A (fr)
NL (1) NL6818027A (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165376A (en) * 1971-01-29 1979-08-21 Lake Shore Roentgenology, Ltd. Treatment of the acute after-effects resulting from alcohol ingestion
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
EP1306376A1 (fr) * 2001-10-25 2003-05-02 Biofrontera Pharmaceuticals AG Dérives de 4-(thio- or selenoxanthene-9-ylidene)-piperidine ou acridine et leur application comme antagonistes selectives de 5-HT2B
US7060711B2 (en) * 2001-10-25 2006-06-13 Biofrontera Bioscience Gmbh Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
CA2530444C (fr) 2003-06-27 2012-03-13 Janssen Pharmaceutica, N.V. Modulateurs du recepteur opioide tricycliques
CN101039940A (zh) * 2004-08-05 2007-09-19 詹森药业有限公司 三环δ－阿片样物质调节剂
EP1655027A1 (fr) * 2004-11-04 2006-05-10 Biofrontera Pharmaceuticals GmbH Utilisation du 9-(N-methyl-piperidyliden-4)-thioxanthene pour le traitement de l'hypertension pulmonaire et la migraine
CA2592462A1 (fr) * 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Modulateurs des recepteurs opioides delta tricycliques
EA011674B1 (ru) * 2004-12-22 2009-04-28 Янссен Фармацевтика Н.В. ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
BRPI0519201A2 (pt) * 2004-12-22 2008-12-30 Janssen Pharmaceutica Nv moduladores de delta-opiàide tricÍclico
JP2008526878A (ja) * 2005-01-06 2008-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 三環式δ−オピオイド調節剤
BRPI0611885A2 (pt) * 2005-06-16 2010-10-05 Janssen Pharmaceutica Nv moduladores opióides tricìclicos
WO2014117863A1 (fr) 2013-02-01 2014-08-07 Biofrontera Bioscience Gmbh Formes polymorphes de sels d'addition d'acide de thioxanthène-9-ylidène-1-méthylpipéridines utilisés comme composés antimigraineux

Also Published As

Publication number Publication date
IE32612L (en) 1969-07-09
NL6818027A (fr) 1969-07-11
FR8187M (fr) 1970-09-07
IE32612B1 (en) 1973-10-03
GB1247801A (en) 1971-09-29
CA921402A (en) 1973-02-20
BR6905370D0 (pt) 1973-02-08
AT305491B (de) 1973-02-26
BE726570A (fr) 1969-07-07
DE1900307A1 (de) 1969-09-04
IL31384A0 (en) 1969-03-27
US3557287A (en) 1971-01-19

Similar Documents

Publication Publication Date Title
IL31384A (en) Pharmaceutical preparations containing a vasotoxic effect of the hepatic acid of type peptide and 9-) 1-methyl-4-piperidilide (thioxanthane
US4309404A (en) Sustained release pharmaceutical compositions
CA1300510C (fr) Composition stabilisee contenant une enzyne convertissant l'angiotensine
AU593051B2 (en) Method of treating alzheimer's disease
KR960000430B1 (ko) 산화에 안정한 약제 조성물
DK172893B1 (da) Lægemiddelpræparat med protraheret virkning og fremgangsmåde til fremstilling heraf
PL324988A1 (en) Orally administered readily dissolving compositions for dopamine antagonists
JP2852608B2 (ja) 口腔乾燥症治療剤
JPS591412A (ja) 脳血管不全症処置用固形製剤
WO1999062560A1 (fr) Stabilisation de compositions contenant des inhibiteurs de l'enzyme de conversion d'angiotensine utilisant de l'oxyde de magnesium
KR920006908B1 (ko) 디히드로피리딘을 함유하는 고상 약제의 제조 방법
US3679798A (en) Composition comprising arylaminooxazoline and antichloligeneric agent
US3673163A (en) Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
IE74211B1 (en) Pharmacologically enhanced formulations
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
RU96120415A (ru) Противокашлевая композиция, содержащая противокашлевое средство и бензидамин
US3755586A (en) Anti tussive compositions containing piperidine derivatives
EA200100869A1 (ru) Кристаллическая форма эплеренона
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
EP1200088B1 (fr) Composition pharmaceutique contenant paracetamol et drotaverine
US3360434A (en) Method for reducing blood pressure with phenylalanine derivatives
US4810707A (en) Herpes simplex treatment
US3795736A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent
CA1060344A (fr) Agent antihypertonique
US4363809A (en) Organic compounds